Assessment of osteoclast number and function: Application in the development of new and improved treatment modalities for bone diseases

Osteoporosis International

Volumn 18, Issue 5, 2007, Pages 681-685

  Henriksen, K ^a   Tanko, L B ^b   Qvist, P ^a   Delmas, P D ^c   Christiansen, C ^b   Karsdal, M A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

CTX I; Osteoclast number; Resorption; TRAcP; TRAP 5b

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; AZD 0530; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; CHLORIDE CHANNEL BLOCKING AGENT; DENOSUMAB; ESTROGEN; NS 3696; OSTEOCLAST DIFFERENTIATION FACTOR ANTIBODY; PHOSPHATASE; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE ATROPHY; BONE DEMINERALIZATION; BONE DISEASE; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; DRUG SAFETY; DRUG TARGETING; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSSIFICATION; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACID PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CATHEPSINS; CELL COUNT; CELL DIFFERENTIATION; COLLAGEN TYPE I; FEMALE; HUMANS; ISOENZYMES; OSTEOCLASTS; OSTEOPETROSIS; OSTEOPOROSIS; PEPTIDES;

EID: 34047185276     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0286-8     Document Type: Article

References (45)

1. Baron R (2003) Anatomy and biology of bone matrix and cellular elements. Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 1-8
2. Martin TJ (1993) Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121-125
3. Vaananen HK, Harkonen PL (1996) Estrogen and bone metabolism. Maturitas 23 Suppl:S65-S69
4. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137
5. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508-1514
6. Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526-1536
7. Ravn P, Hosking D, Thompson D et al (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
8. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237-244
9. Holzer G, Noske H, Lang T (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13-17
10. Gertz BJ, Clemens JD, Holland SD et al (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102-106
11. Woitge HW, Pecherstorfer M, Li Y (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792-801
12. Christgau S, Bitsch-Jensen O, Hanover BN et al (2000) Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505-511
13. Halleen JM, Alatalo SL, Suominen H et al (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337-1345
14. Kirstein B, Chambers TJ, Fuller K (2006) Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem 98:1085-1094
15. Schaller S, Henriksen K, Sveigaard C et al (2004) The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144-1153
16. Karsdal MA, Henriksen K, Sorensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467-476
17. Koh AJ, Demiralp B, Neiva KG et al (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596
18. Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81
19. Reszka AA, Rodan GA (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1:45-52
20. Nenonen A, Cheng S, Ivaska KK et al (2005) Serum TRACP 5b Is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804-1812
21. McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
22. Hamdy NA (2006) Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep 8:50-54
23. Hannon RA, Clowes JA, Eagleton AC et al (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187-194
24. Tahtela R, Seppanen J, Laitinen K et al (2005) Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 16:1109-1116
25. Hansdottir H, Franzson L, Prestwood K et al (2004) The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779-783
26. Hannon RA, Clack G, Gallager N et al (2005) The effect of AZ0530, a highly selective SRC inhibitor, on bone turnover in healthy males. European Calcified Tissue Society Conference 2005 [Abstract nb OC042]
27. Capparelli C, Morony S, Warmington KS et al (2000) Pharmacologic Effects of a Single Treatment with Osteoprotegerin (OPG) on Bone Remodeling and Bone Density in Normal Rats. J Bone Miner Res 15 [Suppl 1], abstract 1132
28. Kostenuik P, Warmington KS, Grisanti M et al (2005) RANKL Inhibition with AMG 162, a Fully Human MAb, Causes Sustained Suppression of Bone Resorption and Increased BMD in Knockin Mice Expressing Humanized RANKL. J Bone Miner Res 20 [Suppl 1], abstract SU304
29. Karsdal MA, Hjorth P, Henriksen K et al (2003) Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975-44987
30. Henriksen K, Gram J, Schaller S et al (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing Autosomal Dominant Osteopetrosis type II (ADOII). Am J Pathol 164:1537-1545
31. Bollerslev J, Marks SC Jr, Pockwinse S et al (1993) Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865-869
32. Alatalo SL, Ivaska KK, Waguespack SG et al (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883-890
33. Del Fattore A, Peruzzi B, Rucci N et al (2005) Clinical, genetic and cellular analysis of forty-nine osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315-325
34. Schlemmer A, Hassager C, Jensen SB et al (1992) Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476-480
35. Qvist P, Christgau S, Pedersen BJ et al (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57-61
36. Hart SM, Eastell R (1999) Biochemical markers of bone turnover. Curr Opin Nephrol Hypertens 8:421-427
37. Simmons DJ, Menton DN, Russell JE et al (1988) Bone cell populations and histomorphometric correlates to function. Anat Rec 222:228-236
38. Halleen JM (2003) Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23:1027-1029
39. Ple PA, Green TP, Hennequin LF et al (2004) Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 47:871-887
40. Meier C, Meinhardt U, Greenfield JR et al (2006) Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 52:1-10
41. Ljusberg J, Wang Y, Lang P et al (2005) Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 280:28370-28381
42. Rissanen J, Suutari S, Ylonen S et al (2005) The Ratio of Osteoclast Activity/Osteoclast Number (CTX/TRACP 5b) Improves the Interpretation of the Effects of Anti-Resorptive Treatments in Human Osteclast Cultures. J Bone Miner Res 20 [Suppl 1], abstract SU290
43. Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
44. Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
45. Heaney RP (2003) Is the paradigm shifting? Bone 33:457-465